Question 1

What is BioMarin Pharmaceuticals Inc's WACC?

Accepted Answer

BioMarin Pharmaceuticals Inc (BMRN) has a Weighted Average Cost of Capital (WACC) of 7.13%. This is calculated using a Cost of Equity of 7.86% (via CAPM with a beta of 0.70) and a pre-tax Cost of Debt of 2.00%, with an equity weight of 88.26% in the capital structure.

Question 2

Is BioMarin Pharmaceuticals Inc's WACC high or low?

Accepted Answer

BioMarin Pharmaceuticals Inc's WACC of 7.13% is below the typical range of 8-12% for most companies, indicating relatively low cost of capital and lower risk. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is BioMarin Pharmaceuticals Inc's WACC calculated?

Accepted Answer

BioMarin Pharmaceuticals Inc's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 7.86% is derived from the CAPM model using a beta of 0.70. The pre-tax Cost of Debt (Rd) is 2.00%. The capital structure is 88.26% equity and 11.74% debt.

BioMarin Pharmaceuticals Inc (BMRN) — WACC 分析

WACC 构成

解读

BioMarin Pharmaceuticals Inc（BMRN）WACC：7.13%

WACC计算器

BioMarin Pharmaceuticals Inc（BMRN） WACC 解读

BMRN 公司分析

BMRN DCF 估值

继续做同行对比